Systemic Injection of Substance P Promotes Murine Calvarial Repair Through Mobilizing Endogenous Mesenchymal Stem Cells

Yueling Zhang, Shu An, Jin Hao, Feng Tian, Xinyi Fang, Jun WangScientific 2018 · DOI

TL;DR

This study demonstrates that systemic injection of Substance P can effectively promote the repair of critical-sized calvarial bone defects in mice. It achieves this by mobilizing endogenous mesenchymal stem cells (MSCs) and simultaneously reducing inflammation, leading to improved bone regeneration and enhanced survival of co-administered MSCs.

What Problem Does This Paper Address?

Craniofacial defects pose a significant challenge in clinical practice, impacting patients' quality of life. While mesenchymal stem cell (MSC) transplantation is a promising therapeutic approach for tissue repair, a major hurdle is the low survival rate of transplanted cells, which compromises regenerative outcomes. An alternative strategy gaining traction is the mobilization of endogenous MSCs, which bypasses the need for exogenous cell transplantation. This paper investigates the potential of Substance P, a known injury-inducible messenger, to mobilize endogenous MSCs and promote calvarial bone repair, addressing the limitations of current MSC-based therapies.

Methods

The researchers employed a multi-faceted approach to investigate the effects of Substance P on calvarial bone repair:

  • Animal Model: A critical-sized calvarial defect model was established in C57BL/6 mice.
  • Substance P Administration: Substance P was administered systemically via tail vein injection.
  • Flow Cytometry: This technique was used to quantify and characterize the mobilization of endogenous CD45<sup>-</sup>CD11b<sup>-</sup>CD29<sup>+</sup> MSCs in peripheral blood after Substance P treatment.
  • Micro-CT Imaging: This non-invasive imaging modality was used to assess the extent of bone regeneration and analyze various bone parameters (volume, density, thickness, etc.) in the calvarial defects.
  • ELISA and Western Blot: These biochemical assays were employed to measure the levels of pro-inflammatory cytokines (IFN-γ, TNF-α) and the anti-inflammatory protein TSG-6 in both peripheral blood and local tissue. Protein expression of Runx2, a key factor in osteogenesis, was also assessed.
  • RT-PCR: This method was used to quantify the mRNA expression levels of inflammatory cytokines and TSG-6.
  • In Vivo GFP Imaging: To assess the survival of transplanted MSCs, GFP-labeled MSCs were used, and their signal was tracked in vivo.
  • Cell Culture and CCK-8 Assay: Isolated endogenous MSCs were cultured in vitro and treated with Substance P to evaluate its effect on cell proliferation.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from animal models and in vitro cell cultures.

Key Insights and Ideas

  • Substance P as a Mobilization Agent: The study confirms that systemic Substance P administration effectively mobilizes endogenous CD45<sup>-</sup>CD11b<sup>-</sup>CD29<sup>+</sup> MSCs from the bone marrow into the peripheral circulation, even in the context of a bone injury. This suggests Substance P could be a valuable tool for harnessing the body's own regenerative potential.
  • Dual Action: Mobilization and Anti-inflammation: Beyond simply mobilizing MSCs, Substance P also demonstrably reduces systemic and local inflammation by decreasing pro-inflammatory cytokines like IFN-γ and TNF-α. This anti-inflammatory effect is crucial, as inflammation can hinder tissue repair.
  • Synergistic Effect with Transplanted MSCs: Combining systemic Substance P with local transplantation of GFP<sup>+</sup> MSCs led to superior bone repair compared to either treatment alone. This highlights a potential synergistic effect where Substance P not only mobilizes endogenous cells but also enhances the survival and efficacy of exogenous MSCs.
  • TSG-6 as a Mediator: The study observed increased levels of TSG-6, an anti-inflammatory protein, in response to Substance P treatment. This suggests that Substance P-mobilized MSCs might contribute to the anti-inflammatory milieu by secreting TSG-6, similar to how exogenous MSCs have been shown to do.
  • Runx2 Upregulation: Substance P treatment, particularly in combination with transplanted MSCs, led to increased Runx2 expression, indicating enhanced osteogenic potential, which is critical for bone formation.

Key Results

  • Systemic Substance P injection significantly increased the absolute and relative numbers of CD45<sup>-</sup>CD11b<sup>-</sup>CD29<sup>+</sup> MSCs in peripheral blood of mice with calvarial defects.
  • Micro-CT analysis revealed that Substance P treatment significantly improved calvarial bone repair, with smaller defect areas and increased new bone formation.
  • Substance P administration led to a significant reduction in IFN-γ and TNF-α levels in both peripheral blood and local defect tissues.
  • TSG-6 levels were significantly elevated in peripheral blood and local tissues following Substance P treatment.
  • Real-time in vivo GFP imaging showed significantly higher GFP signal (indicating surviving transplanted MSCs) in the GFP<sup>+</sup> MSC + i.v. Substance P group compared to the GFP<sup>+</sup> MSCs-scaffold group.
  • Western blot and RT-PCR analyses indicated increased Runx2 expression in the GFP<sup>+</sup> MSC + i.v. Substance P group.
  • In vitro studies showed that Substance P stimulated the proliferation of isolated CD45<sup>-</sup>CD11b<sup>-</sup>CD29<sup>+</sup> cells.

Limitations and Future Work

  • Origin of Mobilized MSCs: While the study suggests mobilized MSCs may originate from bone marrow, definitive proof of their origin is lacking due to current technical limitations. Future work could focus on tracing the origin of these cells.
  • Mechanism of MSC Survival Enhancement: The exact mechanisms by which Substance P promotes the survival of local-transplanted MSCs are not fully elucidated. Further in vitro and in vivo experiments are needed to clarify these pathways.
  • Clinical Translation: The study was conducted in a murine model. Further research is needed to assess the safety and efficacy of Substance P in larger animal models and eventually in human clinical trials for craniofacial defect repair.
  • Long-term Effects: While the study demonstrates improved bone repair, long-term functional outcomes and potential side effects of Substance P administration would be valuable to investigate.

Summary updated

Abstract

Craniofacial defect is a critical problem in dental clinic, which has a tremendous impact on patients' quality of life. Mesenchymal stem cell-based therapy has emerged as a promising approach for tissue defect repair. However, reduced survival after mesenchymal stem cells (MSCs) transplantation remains as a major problem in this area, which hampers the outcome of regeneration. Recently, the mechanism to mobilize endogenous MSCs for tissue regeneration has received increasing attentions, as it does not require exogenous cell transplantation. The primary goal of this study was to confirm the role of intravenous substance P in mobilizing endogenous CD45<sup>-</sup>CD11b<sup>-</sup>CD29<sup>+</sup> MSCs in critical-sized bone defect animals and to investigate the effects of substance P on calvarial bone repair. Flow cytometry analyses revealed that intravenous substance P promoted the mobilization of endogenous CD45<sup>-</sup>CD11b<sup>-</sup>CD29<sup>+</sup> MSCs after bone defect. In addition, Micro-CT showed that intravenous substance P improved the outcomes of calvarial bone repair. Furthermore, we discovered that systemic injection of substance P attenuated inflammation and enhanced the survival of the local-transplanted GFP<sup>+</sup> MSCs. Our findings suggested that substance P together with its mobilized CD45<sup>-</sup>CD11b<sup>-</sup>CD29<sup>+</sup> MSCs helped improve calvarial defect repair through regulating inflammatory conditions and promoting the survival of local-transplanted cells.
BibTeX
@inproceedings{zhang2018systemic,
  author = {Yueling Zhang and Shu An and Jin Hao and Feng Tian and Xinyi Fang and Jun Wang},
  title = {{Systemic Injection of Substance P Promotes Murine Calvarial Repair Through Mobilizing Endogenous Mesenchymal Stem Cells}},
  booktitle = {Scientific},
  year = {2018},
  doi = {10.1038/s41598-018-31414-5},
}
Figure